A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-28

Study Completion Date

2020-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

NCT03657446

Healthy Subjects

COMPLETED PHASE1

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

NCT03494907

Healthy

COMPLETED PHASE1

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

NCT05933447

Healthy

COMPLETED PHASE1

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

NCT04281342

Healthy Subjects

COMPLETED PHASE1

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

NCT02537288

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Single-center, randomized, double-blind, placebo- and moxifloxacin-controlled, Phase 1 study

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A: Daridorexant 50 mg

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Group Type EXPERIMENTAL

Daridorexant

Intervention Type DRUG

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Treatment B: Daridorexant 200 mg

Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.

Group Type EXPERIMENTAL

Daridorexant

Intervention Type DRUG

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Treatment C: Placebo

Placebo administered as tablets (4 x 50 mg) for oral use.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered as tablets for oral use.

Treatment D: Moxifloxacin 400 mg

Moxifloxacin administered as film-coated tablets for oral use.

Group Type ACTIVE_COMPARATOR

Moxifloxacin

Intervention Type DRUG

Moxifloxacin administered as film-coated tablets for oral use.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Daridorexant

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

Intervention Type DRUG

Placebo

Placebo administered as tablets for oral use.

Intervention Type DRUG

Moxifloxacin

Moxifloxacin administered as film-coated tablets for oral use.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent in the local language prior to any study-mandated procedure.
* Czech citizen with the ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.
* Healthy male and female subjects aged 18 to 55 years (inclusive) at Screening.
* 12-lead safety ECG: QTcF \< 450 ms for male subjects and \< 470 ms for female subjects, QRS \< 110 ms, and PR \< 220 ms, and resting HR \> 50 bpm and \< 90 bpm with no clinically relevant abnormalities on 12-lead ECG after 5 min in the supine position at Screening and on Day 1 pre-dose of Period 1.
* Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
* Women of childbearing potential are eligible only if the following applies:

1. Negative serum pregnancy test at Screening.
2. Negative serum pregnancy test on Day 1 of the first period.
3. Agreement to consistently and correctly use a highly effective method of contraception with a failure rate of \< 1% per year, be sexually inactive, or have a vasectomized partner from Screening up to at least 30 days after last study treatment administration in the last period with wash-out periods included. If a hormonal contraceptive is used, it must be initiated at least 1 month before first treatment administration.
* Women of non-childbearing potential must meet at least one of the following criteria:

1. Previous bilateral salpingectomy, salpingo-oophorectomy, or hysterectomy.
2. Premature ovarian failure confirmed by a specialist gynecologist.
3. Post-menopausal, defined as 12 consecutive months with amenorrhea prior to Screening without alternative medical cause and confirmed with follicle-stimulating hormone (FSH) test.
4. XY genotype.
5. Turner syndrome.
6. Uterine agenesis.

Exclusion Criteria

* Pregnant or lactating women.
* Previous exposure to daridorexant.
* Known hypersensitivity to moxifloxacin or any of the drug product excipients or to other fluoroquinolone antibiotics.
* Any contraindication to moxifloxacin treatment.
* History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed).
* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
* History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, second- or third-degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation) or electrolyte disturbances, particularly hypokalemia.
* Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep disorders, restless legs syndrome, nightmare disorder, non-rapid eye movement sleep arousal disorders (sleep terror disorder or sleepwalking disorder), rapid eye movement sleep behavior disorder, circadian rhythm sleep-wake disorders.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes